MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy episode artwork

EPISODE · Feb 3, 2023 · 11 MIN

MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy

from MPR Weekly Dose

The FDA make major revisions to COVID-19 antiretrovirals; Large study finds possible new indication for beta blockers; Jesduvroq approved; Artificial tears product recalled; Evusheld emergency use authorization halted.

Episode metadata supplied by the publisher feed · Published Feb 3, 2023

Embed this episode

Ready to play

MPR Weekly Dose 146 — Paxlovid, Lagevrio EUA Revised; Beta Blockers and Violence; Jesduvroq Approved; Artificial Tears Product Recall; FDA Halt Use of COVID Therapy

0:00 11:54

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 11 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on February 3, 2023.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!